Physician profile
Jonathan E Zuckerman
NPI 1205246337
$23,868.62
in general payments reported to CMS, 2019-2025
7 companies · $7,978 in 2025
The $7,978 reported for 2025 was more than what 88% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,744 · 2020: $975 · 2021: $300 · 2022: $5,080 · 2023: $2,400 · 2024: $2,391 · 2025: $7,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,098.00 |
| Food and Beverage | $671.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $15,075.00 | 2019-2024 | Hydromark Breast Biopsy Site Marker |
| Apellis Pharmaceuticals, INC. | $4,074.33 | 2025 | Empaveli |
| Amgen INC. | $3,678.00 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $533.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $254.27 | 2024-2025 | |
| Travere Therapeutics, INC. | $128.40 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.